Market & Disease Burden

Indication-level prevalence, treatment gaps, and economic impact (2023–2025 sources)

Attention Deficit Hyperactivity Disorder (ADHD)

Prevalence — Adult-Driven Population

  • Adults outnumber children ~2:1 in the U.S. ADHD population: ~15.5M adults (6.0% prevalence) vs ~7M children currently diagnosed (CDC MMWR, Oct 2024).
  • Adult diagnoses rose ~15.2% from 2020 to 2023; pediatric incidence remained stable over the same period (Psychiatric Research and Clinical Practice 2024).
  • Approximately half of U.S. adults with ADHD received their diagnosis at age 18 or older (CDC MMWR, Oct 2024).
  • Children/adolescents: community-based prevalence ~5–6%; clinical-setting prevalence up to 32% (Mol Psychiatry 2025 meta-analysis).
  • Adults: community-based prevalence ~2.5–3%; clinical-setting prevalence ~21%.
  • Global ADHD therapeutics market: ~$15B in 2025, projected $24–32B by 2035 — growth predominantly adult-driven.

Economic Burden (United States)

  • Adult societal cost: ~$122.8 billion/year (~$14,092 per adult, 2018 dollars).
  • Children: ~$19.4 billion/year. Adolescents: ~$13.8 billion/year.
  • Combined US societal cost: ~$156 billion annually.
  • Largest cost drivers: unemployment (~54%), productivity loss (~23%), healthcare services (~12%).

Current Treatment Landscape and Unmet Needs

  • Schedule II access friction: per CDC MMWR (Oct 2024), only ~33% of the ~15.5M U.S. adults with current ADHD diagnosis filled a stimulant in the prior 12 months, and 71.5% of those on stimulants reported difficulty filling prescriptions due to unavailability — driven by DEA manufacturing quotas, supply shortages, and restrictive prescribing.
  • Tolerability: common adverse effects lead to discontinuation in a meaningful share of patients.
  • Duration: daily symptom coverage remains imperfect with current formulations.
  • Non-responders: a substantial subset of patients responds poorly to existing stimulants.
  • Non-stimulant gap: existing non-stimulant options offer convenience but below-stimulant efficacy.

Apathy in Alzheimer's Disease

Prevalence and Clinical Impact

  • Apathy affects up to ~70% of AD patients; published range 26–82% depending on assessment method.
  • Estimated 17–24 million people globally living with apathy in AD.
  • Apathy is the most common neuropsychiatric symptom in AD and a major driver of caregiver distress and earlier institutionalization.
  • Each increment in apathy severity correlates with a ~4.1% rise in monthly care costs.

Treatment Landscape

  • No FDA-approved treatment currently exists for apathy in AD.
  • Off-label methylphenidate shows modest efficacy in NIH-funded trials but limited clinical adoption due to Schedule II restrictions.
  • The recent approval of an agitation-in-AD therapy establishes a regulatory precedent for treating behavioral symptoms in AD.

Global Dementia Context and Economic Impact

  • ~57 million people worldwide currently live with dementia; projected to reach 139–153 million by 2050 (ADI / GBD-2019).
  • Global annual cost of dementia: ~$1.3 trillion; projected to reach $2.8 trillion by 2030.
  • United States dementia spending: ~$360 billion annually (Alzheimer's Association 2024 Facts & Figures).
  • Apathy alone is estimated to add ~$4.5 billion in additional US dementia-care costs annually (conservative estimate).
  • Informal caregivers account for ~88% of monthly care costs in AD patients with apathy.

Apathy in Frontotemporal Dementia (bvFTD)

Prevalence and Clinical Impact

  • FTD prevalence in US adults aged 45–64: ~15–22 per 100,000; behavioral-variant FTD (bvFTD) ~10 per 100,000 globally.
  • Estimated ~60,000 bvFTD patients in the United States.
  • Apathy occurs in up to ~90% of bvFTD patients and is the #1 driver of caregiver burden in this population.
  • Mean age of onset ~58 years; mean survival from diagnosis ~4.5 years.

Therapeutic Gap

  • No FDA-approved therapies for any FTD indication.
  • Complete therapeutic void supports orphan-indication regulatory pathway and premium market positioning.

Post-TBI Cognitive Deficits

Cognitive Outcomes

  • ~13.5% of mild-TBI patients show poor cognitive outcomes at 1 year versus ~4.5% of healthy controls (TRACK-TBI, 2022).
  • Chronic TBI (>1 year post-injury): ~20–23% show predominant cognitive deficits as a phenotype (2025 phenotype studies).
  • Predominant cognitive-deficit phenotypes correlate with lower cortical volume across executive control, dorsal attention, and default-mode networks.

Therapeutic Context

  • Stimulants are used off-label for post-TBI cognitive and motivational symptoms.
  • No FDA-approved therapy specifically targets cognitive or motivational deficits post-TBI.

Sources & References (2023–2025)

  1. Prevalence of ADHD in pediatric and adult clinical settings: systematic review and meta-analysis. Molecular Psychiatry 2025. link.springer.com
  2. Incidence, prevalence, and global burden of ADHD from 1990 to 2019: GBD analysis. Molecular Psychiatry 2023. nature.com
  3. Economic burden of ADHD among adults in the United States: a societal perspective. 2024. PMC12128943
  4. Centers for Disease Control and Prevention. ADHD data and statistics. cdc.gov
  5. Staley BS, Robinson LR, Claussen AH, et al. ADHD Diagnosis, Treatment, and Telehealth Use in Adults — NCHS Rapid Surveys System, United States, Oct–Nov 2023. MMWR Morb Mortal Wkly Rep 2024;73:890–895. cdc.gov/mmwr
  6. Incidence of ADHD between 2016 and 2023: a retrospective cohort. Psychiatric Research and Clinical Practice 2024. psychiatryonline.org
  7. An Update on Apathy in Alzheimer's Disease. Geriatrics (MDPI) 2023. mdpi.com
  8. Apathy associated with Alzheimer's disease. PMC. PMC12079319
  9. Kruse C. et al. Economic impact of apathy in AD. Alzheimer's & Dementia 2023.
  10. Alzheimer's Disease International. Dementia statistics. alzint.org
  11. GBD 2019 Dementia Forecasting Collaborators. Estimation of global prevalence of dementia in 2019 and forecasted prevalence in 2050. Lancet Public Health. healthdata.org
  12. Alzheimer's Association. 2024 Alzheimer's Disease Facts & Figures.
  13. Incidence and prevalence of frontotemporal dementia: systematic review and meta-analysis. 2025. PMC12418226
  14. Depression and apathy in frontotemporal dementia: a short assessment of facts and outlook. J Neural Transmission 2025. link.springer.com
  15. Cognitive outcome 1 year after mild traumatic brain injury (TRACK-TBI study). Neurology 2022. pubmed.ncbi.nlm.nih.gov
  16. Distinct clinical phenotypes and neuroanatomic correlates in chronic TBI. medRxiv 2025. medrxiv.org